lassa
viru
lasv
belong
famili
arenavirida
envelop
singlestrand
rna
virus
distribut
worldwid
base
antigen
relationship
geograph
distribut
arenavirus
divid
two
major
group
old
world
group
includ
prototyp
famili
lymphocyt
choriomening
viru
lcmv
lasv
endem
west
african
countri
caus
everi
year
thousand
human
infect
hemorrhag
fever
sever
clinic
manifest
new
world
group
includ
among
other
machupo
junin
guanarito
sabia
virus
caus
viral
hemorrhag
fever
vhf
except
new
world
viru
tacarib
isol
artibeu
bat
arenavirus
rodentborn
virus
past
year
great
effort
made
find
potenti
therapeut
vaccin
approach
arenaviru
field
review
specif
effect
treatment
avail
combat
hemorrhag
fever
caus
arenavirus
administr
convalesc
plasma
report
reduc
mortal
rate
patient
argentin
hemorrhag
fever
howev
immuneplasma
recipi
develop
late
neurolog
syndrom
unknown
origin
exist
drug
use
treat
lassa
fever
certain
south
american
hemorrhag
fever
broadspectrum
antivir
agent
ribavirin
ribonucleosid
analogu
shown
partial
effect
given
earli
cours
ill
even
though
drug
rel
inexpens
patient
highdevelop
countri
still
unafford
mani
live
west
africa
south
america
moreov
sever
advers
effect
associ
ribavirin
therapi
patient
studi
anim
model
lack
effect
diseas
control
measur
well
discoveri
new
fatal
arenaviru
speci
pose
risk
epidem
potenti
emphas
need
novel
therapeut
intervent
lassa
virion
pleomorph
lipidenvelop
particl
contain
two
singlestrand
rna
segment
design
l
larg
small
encod
four
viral
protein
uniqu
ambisens
code
strategi
l
segment
encod
viral
rnadepend
rna
polymeras
l
small
zinc
finger
matrix
protein
z
segment
encod
viru
nucleoprotein
np
viru
surfac
glycoprotein
precursor
pregpc
pregpc
cleav
cotransl
stabl
signal
peptid
gpc
posttransl
matur
cleavag
gpc
proprotein
convertas
site
proteas
also
known
subtilisin
kexin
lead
gener
distal
receptorbind
subunit
transmembranespan
fusion
compet
subunit
togeth
signal
peptid
subunit
form
tripartit
glycoprotein
spike
complex
viral
surfac
glycoprotein
old
world
arenavirus
lasv
lcmv
first
viral
glycoprotein
shown
proteolyt
process
normal
play
import
physiolog
regulatori
role
cholesterol
metabol
er
stress
respons
cartilag
develop
cellular
process
use
systemat
mutat
analysi
lcmv
gp
cleavag
site
consensu
motif
r
rkh
l
alstf
determin
conserv
glycoprotein
sequenc
old
world
virus
lasv
mopeia
mobala
well
new
world
viru
pichind
suggest
arenaviru
glycoprotein
cleav
inde
recent
rojek
et
al
report
glycoprotein
new
world
hemorrhag
fever
virus
junin
machupo
guanarito
also
process
although
guanarito
possess
proteas
recognit
motif
differ
known
arenaviru
gp
consensu
cleavag
sequenc
indic
broader
substrat
specif
previous
anticip
proteolyt
activ
lasv
gpc
necessari
transport
gpc
cell
surfac
bud
arenavirus
occur
essenti
incorpor
cleav
subunit
virion
thu
format
infecti
viral
particl
absenc
gpc
cleavag
envelop
noninfecti
lasvlik
particl
releas
contain
l
np
z
protein
viral
rna
devoid
viral
glycoprotein
similar
result
describ
lcmv
new
world
hemorrhag
fever
virus
addit
import
role
arenavir
life
cycl
critic
infect
crimeancongo
hemorrhag
fever
viru
cchfv
member
bunyavirida
famili
process
glycoprotein
gn
find
make
inhibit
particularli
interest
develop
novel
antivir
therapeut
target
pathogen
virus
known
process
success
approach
inhibit
proprotein
convertas
involv
genet
engin
antitrypsin
deriv
serin
proteas
inhibitor
serpin
characterist
expos
reactiv
center
loop
rcl
mediat
bind
activ
site
target
proteas
explor
potenti
use
modifi
antitrypsin
alter
inhibitori
spectrum
guid
discoveri
natur
variant
known
pittsburgh
found
patient
sever
bleed
disord
caus
mutat
reactiv
center
residu
antitrypsin
methionin
arginin
substitut
chang
specif
elastas
thrombin
coagul
proteas
due
introduct
second
mutat
alanin
arginin
rcl
engin
variant
portland
show
high
affin
furin
effici
inhibit
format
infecti
hiv
measl
viru
human
cytomegaloviru
progeni
block
furindepend
process
glycoprotein
gb
respect
pullikotil
cowork
use
approach
gener
highli
select
variant
specif
introduc
variou
recognit
motif
rcl
adapt
toward
effici
inhibit
process
substrat
sterol
regulatori
element
bind
protein
activ
transcript
factor
well
cchfv
glycoprotein
howev
effect
inhibitor
cchfv
infect
analyz
studi
block
cleavag
lasv
glycoprotein
gener
recombin
variant
mimick
recognit
motif
rril
rrvl
rryl
exhibit
greatest
inhibitori
potenti
base
immunoblot
quantif
addit
use
construct
contain
lasv
gp
cleavag
motif
rrll
rcl
use
doxycyclin
regul
express
system
demonstr
variant
effici
block
proteolyt
matur
glycoprotein
precursor
gpc
wherea
furinspecif
effect
gpc
process
viru
replic
replicationcompet
recombin
vesicular
stomat
viru
express
lasv
glycoprotein
gpc
authent
lasv
significantli
inhibit
presenc
degre
inhibit
viral
replic
correl
abil
differ
variant
inhibit
process
lasv
gpc
sinc
glycoprotein
process
endoproteas
critic
viru
infect
lasv
arenavirus
caus
hemorrhag
fever
also
member
bunyavirida
famili
optim
base
find
could
lead
potent
specif
inhibitor
potenti
treatment
certain
vhf
cdna
open
read
frame
rat
gene
bank
access
number
kind
gift
dr
g
thoma
vollum
institut
oregon
health
scienc
univers
portland
usa
insert
use
templat
gener
variant
recombin
polymeras
chain
reaction
pcr
use
overlap
oligonucleotid
sequenc
oligonucleotid
use
list
tabl
result
fulllength
pcr
product
digest
bamhi
nhei
clone
tetracyclin
tet
control
induc
mammalian
express
vector
clontech
accuraci
construct
confirm
dna
sequenc
gener
stabli
express
cell
line
chines
hamster
ovari
cho
teton
cell
clontech
transfect
contain
construct
use
lipofectamin
invitrogen
accord
manufactur
instruct
cell
cultur
week
select
pressur
presenc
hygromycin
b
select
agent
express
plasmid
select
agent
rtta
revers
tetcontrol
transactiv
cassett
select
media
replac
everi
day
wellsepar
antibioticresist
cell
clone
individu
isol
clone
cylind
sigma
therefor
small
volum
trypsinedta
sigma
ad
cultur
dish
incub
briefli
cell
detach
cell
collect
insid
cylind
transfer
individu
well
plate
growth
select
medium
grown
confluenc
cell
transfer
larger
flask
protein
express
induc
doxycyclin
clontech
analyz
western
blot
immunofluoresc
stabl
cell
line
show
similar
express
level
variou
chosen
experi
vero
cell
green
monkey
kidney
cultur
dulbecco
modifi
eagl
medium
dmem
gibco
teton
cell
gibco
media
contain
penicillin
uml
streptomycin
lglutamin
mmoll
invitrogen
well
fetal
bovin
serum
pan
biotech
cell
gener
gift
dr
j
l
goldstein
depart
molecular
genet
univers
texa
southwestern
medic
center
dalla
usa
maintain
cho
cell
supplement
cholesterol
sigma
mm
sodium
mevalon
sigma
sodium
oleat
sigma
vesicular
stomat
viru
revers
genet
system
vsv
indiana
serotyp
kindli
provid
dr
jk
rose
depart
patholog
yale
univers
school
medicin
new
usa
describ
detail
earlier
recombin
vsv
express
glycoprotein
gpc
lassa
viru
lasv
strain
josiah
design
wildtyp
vsv
vsvwt
propag
vero
cell
describ
previous
influenza
viru
design
fowl
plagu
viru
fpv
propag
embryon
hen
egg
store
use
viru
titrat
fpv
describ
previous
experi
infecti
fpv
done
biolog
safeti
level
condit
titrat
perform
use
micropl
format
plaqu
assay
subsequ
immunostain
describ
brief
viru
dilut
incub
vero
cell
overlay
carboxymethylcellulos
cmc
plaqu
format
infect
cell
visual
cell
fixat
paraformaldehyd
pfa
permeabil
tritonx
use
specif
lasv
antibodi
follow
incub
horseradish
peroxidaselabel
secondari
antirabbit
antibodi
dako
final
cell
stain
true
blue
peroxidas
substrat
kpl
viru
spread
experi
cho
cell
line
seed
plate
presenc
absenc
doxycyclin
h
induct
cell
infect
fpv
grown
without
solid
overlay
cell
fix
differ
time
point
postinfect
immunostain
perform
describ
use
rabbit
sera
vsv
kindli
provid
dr
g
herrler
institut
virologi
zentrum
infektionsmedizin
stiftung
hochschul
hannov
germani
detect
infect
cell
fpv
cell
infect
fpv
respect
viru
titrat
lasv
strain
josiah
gene
bank
access
number
perform
defin
tissu
cultur
infecti
dose
vero
cell
grown
plate
confluenc
cell
inocul
serial
dilut
supernat
lasvinfect
cho
cell
line
grown
presenc
absenc
doxycyclin
assay
evalu
day
postinfect
valu
calcul
use
spearmankarb
method
experi
involv
lasvinfect
sampl
perform
biolog
safeti
level
condit
philippsunivers
marburg
h
postinfect
cell
cultur
supernat
infect
cell
clear
cell
debri
pellet
rotor
sucros
cushion
rpm
h
pellet
resuspend
pb
buffer
mix
sdspage
sampl
buffer
control
intracellular
express
level
cell
lysat
collect
simultan
sampl
analyz
sdspage
western
blot
use
proteinspecif
antibodi
indic
protein
separ
sdspage
use
polyacrylamid
gel
immunoblot
perform
describ
previous
antiserum
lassa
viru
also
describ
previous
polyclon
rabbit
antibodi
purchas
abcam
uk
monoclon
mous
antiflag
antibodi
sigmaaldrich
secondari
antibodi
label
molecular
probe
invitrogen
biomol
respect
use
visual
quantif
detect
protein
use
odyssey
infrar
imag
system
licor
bioscienc
cho
cell
line
grown
coverslip
h
doxycyclineinduct
cell
wash
pb
fix
pfa
dmem
min
fix
remov
free
aldehyd
quench
mm
glycin
pb
sampl
wash
pb
permeabil
min
pb
contain
triton
cell
incub
block
solut
bovin
serum
albumin
tween
glycerol
sodium
azid
pb
subsequ
stain
primari
mouseantiflag
antibodi
secondari
antimous
antibodi
coupl
rhodamin
jackson
immunoresearch
cell
nuclei
stain
dapi
sigma
microscop
analysi
perform
zeiss
apotomeaxiovert
microscop
use
magnif
replicationcompet
recombin
vesicular
stomat
viru
rvsv
express
foreign
envelop
glycoprotein
demonstr
suitabl
model
system
studi
role
viral
glycoprotein
context
viru
replic
present
studi
took
advantag
rvsv
express
lasv
glycoprotein
gp
design
system
biosynthesi
process
gp
shown
authent
compar
lasv
initi
experi
want
determin
whether
cell
suscept
infect
reason
chose
cell
studi
avail
site
proteasedefici
cho
cell
line
design
cell
gp
matur
abolish
gpdefici
noninfecti
lasv
particl
releas
thu
cell
clone
provid
ideal
control
inhibit
studi
vero
cell
infect
either
wildtyp
vsv
vsvwt
control
aliquot
cell
cultur
supernat
collect
differ
time
infect
analyz
plaqu
assay
growth
kinet
reveal
grow
similar
titer
cell
compar
vero
cell
use
earlier
studi
fig
data
demonstr
cell
support
effici
replic
thu
use
tool
investig
expect
lack
effici
replic
cell
wherea
viru
growth
vsvwt
remain
unaffect
cell
fig
reason
low
detect
viru
titer
supernat
cell
current
known
also
observ
lasv
present
studi
lcmv
new
word
arenavirus
glycoprotein
activ
yet
unknown
proteas
though
low
effici
might
explain
phenomenon
mimic
condit
shortterm
treatment
decid
use
induc
doxycyclinedepend
teton
express
system
allow
regul
express
protein
interest
determin
whether
treatment
cell
doxycyclin
interfer
viral
replic
cultiv
teton
cell
presenc
absenc
doxycyclin
h
h
respect
shown
fig
teton
cell
treat
doxycyclin
produc
viru
titer
compar
cell
cultiv
absenc
doxycyclin
indic
condit
use
experi
influenc
effici
viru
replic
pullikotil
colleagu
recent
report
variou
antitrypsin
mimick
recognit
motif
abl
block
process
substrat
srebp
although
differ
degre
addit
variant
shown
effect
studi
chosen
lasv
gpc
cleavag
motif
rrll
investig
whether
also
inhibit
lasv
gpc
cleavag
therefor
gener
variou
specif
control
furinadapt
recombin
pcr
technolog
use
rat
templat
fig
facilit
detect
introduc
flag
epitop
ctermini
construct
stabl
cell
line
gener
individu
clone
isol
screen
express
doxycyclin
induct
immunoblot
immunofluoresc
analysi
cell
line
show
similar
express
level
chosen
experi
fig
test
inhibitori
potenti
proteolyt
process
lasv
gp
stabli
transfect
teton
cell
nontransfect
wildtyp
teton
cell
well
cell
infect
moi
presenc
absenc
doxycyclin
allow
one
replic
cycl
cell
lysat
analyz
h
postinfect
detect
lasv
gp
cleavag
western
blot
analysi
use
gpspecif
antiserum
recogn
precursor
gpc
cleav
subunit
teton
cell
lasv
gp
effici
cleav
regardless
whether
doxycyclin
present
contrast
virtual
detect
cleavag
gp
observ
cell
defici
fig
lane
without
express
variou
antitrypsin
effici
cleavag
detect
stabli
transfect
cell
line
similar
process
gp
wildtyp
teton
cell
fig
lane
contrast
cell
express
inhibit
proteolyt
matur
lasv
gp
fig
lane
furthermor
result
show
presenc
furinspecif
influenc
lasv
gpc
process
demonstr
specif
gener
fig
lane
quantif
cleavag
reveal
variant
rril
exhibit
greatest
inhibitori
effect
gp
process
inhibit
follow
rrll
inhibit
possess
amino
acid
cleavag
motif
lasv
gpc
also
variant
rrvl
rryl
found
inhibitori
although
lesser
extent
inhibit
less
variant
rril
rrll
fig
taken
togeth
data
clearli
demonstr
effici
block
matur
cleavag
lasv
gp
howev
differ
regard
inhibitori
potenti
shown
earlier
cleavag
gpc
absolut
requir
incorpor
glycoprotein
subunit
virion
envelop
thu
product
infecti
lasv
therefor
address
question
whether
potenti
prevent
gp
incorpor
block
glycoprotein
process
end
rril
cell
infect
presenc
absenc
doxycyclin
either
vsvwt
control
h
postinfect
viral
particl
releas
cell
cultur
supernat
purifi
sucros
cushion
analyz
mean
immunoblot
viral
particl
supernat
noninduc
rril
cell
teton
control
cell
cleav
readili
observ
wherea
particul
materi
isol
supernat
rril
express
cell
glycoprotein
detect
fig
howev
western
blot
analysi
vsv
protein
reveal
releas
viral
protein
supernat
rril
express
cell
consist
earlier
find
absenc
gpc
cleavag
envelop
noninfecti
lasvlik
particl
contain
matrix
protein
z
ribonucleoprotein
rnp
complex
devoid
viral
glycoprotein
still
releas
lower
amount
vsv
protein
observ
cell
lysat
supernat
rril
express
cell
reflect
lower
level
viral
replic
due
less
effici
viru
spread
fig
contrast
abil
effici
block
incorpor
lasv
gp
virion
presenc
rril
effect
releas
glycoprotein
g
contain
wildtyp
vsv
particl
amount
vsv
protein
detect
supernat
rril
express
cell
similar
amount
viral
protein
observ
supernat
noninduc
cell
cell
indic
effici
viral
replic
celltocel
spread
vsvwt
despit
presenc
rril
fig
taken
togeth
data
demonstr
potenti
prevent
lasv
gp
incorpor
inhibit
glycoprotein
cleavag
essenti
prerequisit
infecti
progeni
next
want
know
whether
observ
inhibit
lasv
gp
process
correl
abil
differ
variant
inhibit
viru
spread
investig
establish
plate
assay
infect
cell
immunostain
true
blue
substrat
describ
materi
method
viru
spread
monitor
appear
characterist
cometshap
foci
show
viru
progeni
carri
cell
monolay
prevent
viru
spread
result
limit
radial
growth
due
infect
neighbour
cell
assay
allow
rapid
screen
potenti
inhibitor
end
doxycyclineinduc
noninduc
cho
cell
line
well
teton
cell
cell
infect
h
postinfect
cell
fix
immunostain
noninduc
condit
effici
viru
spread
observ
teton
variant
cell
line
well
teton
wildtyp
cell
fig
upper
panel
contrast
viru
spread
significantli
diminish
cell
express
specif
fig
lower
panel
data
indic
potenti
specif
inhibit
process
lasv
gp
turn
requir
effici
viru
spread
note
infecti
foci
observ
rril
express
cell
larger
compar
cell
virtual
viru
spread
observ
result
singl
infect
cell
fig
although
similar
inhibit
valu
observ
mean
immunoblot
quantif
fig
remain
nondetect
cleavag
event
may
count
limit
celltocel
spread
rril
express
cell
cell
express
furinadapt
variant
rvkr
prevent
viru
spread
first
glanc
rather
observ
enhanc
infect
compar
noninduc
cell
might
due
increas
lasv
cellular
receptor
cell
surfac
confirm
specif
variant
use
fowl
plagu
viru
fpv
contain
hemagglutinin
multibas
cleavag
motif
recogn
furin
thu
furinadapt
prevent
viru
spread
fpv
viru
spread
presenc
remain
unaffect
fig
clearli
demonstr
potent
variant
rril
effect
fpv
replic
viru
spread
found
similar
observ
wild
type
teton
cell
contrast
cell
express
furinadapt
variant
rvkr
viru
spread
fpv
drastic
reduc
wherea
fpv
replic
occur
effici
doxycyclinefre
condit
cell
result
demonstr
gener
variant
exhibit
high
specif
correspond
proteas
essenti
viru
spread
cell
cultur
elucid
effect
differ
variant
multicycl
replic
viral
titer
determin
end
cell
infect
moi
presenc
absenc
doxycyclin
cell
cultur
supernat
collect
h
h
postinfect
viru
titer
determin
plaqu
assay
shown
tabl
noninduc
cell
line
permit
unaffect
growth
compar
titer
wherea
viru
titer
reduc
cell
express
variant
h
postinfect
viru
product
decreas
fold
cell
express
variant
rril
compar
noninduc
control
cultur
presenc
variant
rrll
reduc
viru
titer
supernat
fold
follow
fold
reduct
viru
product
variant
rrvl
express
cell
presenc
variant
rryl
exhibit
moder
inhibitori
effect
viral
replic
inhibit
fold
presenc
furinadapt
variant
rvkr
affect
replic
compar
noninduc
control
cell
result
indic
variou
exhibit
differ
inhibitori
potenti
due
differ
recognit
motif
howev
degre
inhibit
viru
replic
correl
well
inhibitori
potenti
variou
variant
block
lasv
gp
process
interestingli
follow
inhibit
viru
progeni
time
period
h
variant
rril
rrll
sustain
inhibitori
capac
wherea
cell
express
variant
rrvl
rryl
viru
product
found
recov
although
initi
express
level
variant
similar
tabl
data
indic
inhibitori
potenti
variant
rrvl
rryl
suffici
effici
suppress
format
infecti
particl
effect
block
lasv
gpc
cleavag
wherea
variant
rril
rrll
seem
appropri
candid
effici
inhibit
lasv
propag
final
want
investig
impact
block
gp
process
viru
progeni
authent
lasv
therefor
assess
inhibitori
potenti
potent
variant
rril
multipl
lasv
strain
josiah
purpos
rril
cell
control
cell
infect
lasv
moi
induc
express
rril
cell
control
offtarget
effect
teton
cell
cultiv
presenc
doxycyclin
determin
viru
titer
infecti
virion
releas
cell
cultur
supernat
analyz
defin
tissu
cultur
infecti
dose
variou
time
postinfect
indic
noninduc
rril
cell
lasv
reveal
growth
kinet
similar
observ
teton
control
cultur
express
rril
result
averag
reduct
viral
titer
fig
differ
infecti
lasv
titer
supernat
rril
express
cell
cell
correl
limit
viru
spread
observ
rril
express
cell
compar
singl
cell
infect
null
cell
fig
taken
togeth
result
highlight
inhibitori
activ
modifi
lasv
demonstr
inhibit
endogen
potent
strategi
reduc
product
infecti
lasv
progeni
current
drug
treatment
lassa
fever
certain
new
world
hemorrhag
fever
limit
guanosin
analogu
ribavirin
although
ribavirin
therapi
reduc
mortal
rate
sever
clinic
case
unavail
patient
west
africa
south
america
well
associ
sever
advers
effect
includ
anaemia
teratogen
embryo
lethal
argu
develop
new
altern
treatment
option
principl
everi
step
viral
life
cycl
potenti
target
antivir
inhibitor
current
antivir
strategi
arenaviru
field
mainli
target
viru
entri
replic
assembl
inhibit
studi
glycoprotein
activ
endoproteas
impact
viral
replic
larg
unexploit
due
central
role
arenaviru
life
cycl
consid
cellular
target
antivir
drug
develop
present
studi
analyz
inhibitori
effect
proteolyt
process
lasv
gpc
consequ
viral
replic
knowledg
first
report
address
impact
proteinbas
inhibit
lasv
gpc
cleavag
multicycl
replic
furinadapt
shown
effici
inhibit
format
infecti
progeni
virus
eg
hiv
measl
viru
human
cytomegaloviru
use
replicationcompet
recombin
vsv
pseudotyp
lasv
glycoprotein
gp
demonstr
proteolyt
matur
precursor
gpc
sensit
mutagenesi
reactiv
centr
loop
rcl
recognit
motif
rril
result
abrog
gpc
process
similar
observ
cell
inhibitori
activ
variant
rril
lasv
gp
cleavag
describ
agreement
previou
studi
show
inhibitori
potenti
process
natur
substrat
also
variant
contain
lasv
gpc
cleavag
motif
rrll
exhibit
high
inhibitori
potenti
found
drastic
reduc
gp
process
interestingli
variant
exhibit
inhibit
activ
matur
cleavag
artifici
propdgf
precursor
plateletderiv
growth
factor
mutant
process
due
introduct
rrll
cleavag
site
fail
inhibit
cleavag
endogen
express
data
indic
variou
substrat
differ
sensit
toward
inhibit
outcom
sever
ill
increas
significantli
level
viremia
lassa
fever
patient
therefor
extent
multicycl
replic
lasv
thu
load
infecti
particl
host
organ
import
impact
progress
diseas
studi
reveal
variant
rril
rrll
potenc
suffici
sustain
inhibitori
capac
multicycl
replic
result
signific
reduct
viru
infect
inhibit
viral
replic
correl
abil
variant
rril
rrll
effici
inhibit
process
lasv
glycoprotein
precursor
although
data
demonstr
inhibit
glycoprotein
cleavag
rril
reduc
incorpor
subunit
virion
detect
level
viral
titer
rril
express
cell
found
greater
obtain
null
cell
base
observ
consid
even
potent
variant
rril
fail
entir
inhibit
activ
howev
given
import
biolog
function
regul
variou
cellular
process
complet
inhibit
catalyt
activ
desir
variant
rrvl
rryl
observ
similar
inhibit
valu
immunoblot
quantif
analysi
describ
cchfv
gp
cleavag
though
inhibitori
activ
lasv
gpc
cleavag
suffici
effici
reduc
viru
replic
result
taken
consider
experiment
setup
futur
studi
address
impact
inhibit
arenaviru
replic
potent
variant
rril
reveal
similar
inhibitori
potenti
viru
releas
authent
lasv
observ
correspond
pseudotyp
therefor
studi
also
demonstr
replicationcompet
vsv
express
lasv
glycoprotein
excel
surrog
model
analyz
potenti
antivir
target
biolog
function
gp
consequ
viru
replic
studi
perform
biosafeti
level
laboratori
condit
would
otherwis
requir
biosafeti
level
laboratori
condit
taken
togeth
data
indic
may
repres
promis
lead
compound
develop
new
class
antiarenaviru
inhibitor
recent
year
improv
made
applic
bioengin
serpin
combat
bacteri
viral
infect
exampl
addit
exogen
potent
select
furin
inhibitor
found
effici
block
human
cytomegaloviru
infect
howev
contrast
furin
known
recycl
plasma
membran
tgn
via
endosom
compart
membranebound
local
secretori
pathway
sort
endosom
compart
cell
surfac
followup
studi
small
synthet
peptid
deriv
describ
present
work
current
progress
address
cellular
deliveri
organel
specif
target
well
inhibitori
potenti
authent
lasv
replic
analog
inhibit
strategi
eukaryot
subtilas
furin
previous
design
develop
cellperm
peptidyl
chloromethylketon
inhibitor
contain
lasv
gpc
cleavag
site
design
decrrllcmk
irrevers
inhibitor
effici
block
process
lasv
gp
nanomolar
concentr
howev
cell
typedepend
toxic
observ
us
other
potenti
vitro
use
requir
investig
due
essenti
role
cholesterol
metabol
fatti
acid
synthesi
enzym
attract
great
attent
pharmaceut
industri
research
effort
current
direct
toward
develop
inhibitor
may
use
treatment
dyslipidemia
varieti
cardiometabol
risk
factor
associ
diabet
obes
identif
specif
inhibitor
therapeut
area
may
also
benefici
treatment
hemorrhag
fever
caus
virus
known
process
futur
studi
elucid
antivir
efficaci
novel
inhibitor
develop
convent
antivir
drug
target
protein
virusencod
cellular
protein
essenti
viral
replic
current
consid
altern
potenti
target
antivir
therapi
except
ebola
viru
whose
glycoprotein
cleavag
proprotein
convertas
furin
essenti
viru
replic
cell
cultur
virul
nonhuman
primat
matur
cleavag
surfac
glycoprotein
sever
viru
speci
endoproteas
key
determin
host
cell
tropism
pathogen
thu
emerg
viral
escap
mutant
confer
resist
due
target
inhibit
endogen
proteas
rather
unlik
cell
persist
infect
junin
viru
vaccin
strain
candid
viru
escap
variant
possess
cleavag
motif
recognit
motif
evolv
indic
low
potenti
arenavirus
develop
de
novo
differ
glycoprotein
matur
pathway
observ
togeth
find
inhibit
significantli
affect
lasv
gp
process
viru
infect
encourag
develop
inhibitor
potenti
drug
target
counteract
infect
caus
pathogen
arenavirus
